1079-Precision Product Framework for MSC Therapy
This perspective piece argues for a transition from a standardized manufacturing model to a precision product framework in the development of mesenchymal stem/stromal cell (MSC) therapies. The author highlights a critical paradox where regulatory standards prioritize high cell viability, yet therapeutic success in inflammatory diseases often depends on host-mediated clearance of apoptotic cells, a process known as efferocytosis. By recognizing that secretory activity and programmed cell death are complementary mechanisms rather than opposing states, researchers can better match specific cell…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.